JP2022048153A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022048153A5 JP2022048153A5 JP2021213604A JP2021213604A JP2022048153A5 JP 2022048153 A5 JP2022048153 A5 JP 2022048153A5 JP 2021213604 A JP2021213604 A JP 2021213604A JP 2021213604 A JP2021213604 A JP 2021213604A JP 2022048153 A5 JP2022048153 A5 JP 2022048153A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid encoding
- car
- anticancer agent
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020004707 nucleic acids Proteins 0.000 claims 10
- 102000039446 nucleic acids Human genes 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 10
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- -1 c-Met Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 2
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 claims 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 101000610551 Homo sapiens Prominin-1 Proteins 0.000 claims 2
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 2
- 101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102000000704 Interleukin-7 Human genes 0.000 claims 2
- 108010002586 Interleukin-7 Proteins 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000003729 Neprilysin Human genes 0.000 claims 2
- 108090000028 Neprilysin Proteins 0.000 claims 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 2
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims 2
- 102100040120 Prominin-1 Human genes 0.000 claims 2
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 2
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229960000390 fludarabine Drugs 0.000 claims 2
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims 2
- 229940100994 interleukin-7 Drugs 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023097065A JP7527049B2 (ja) | 2014-10-09 | 2023-06-13 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2024113188A JP7755890B2 (ja) | 2014-10-09 | 2024-07-16 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014208200 | 2014-10-09 | ||
| JP2014208200 | 2014-10-09 | ||
| JP2020048623A JP7008350B2 (ja) | 2014-10-09 | 2020-03-19 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020048623A Division JP7008350B2 (ja) | 2014-10-09 | 2020-03-19 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097065A Division JP7527049B2 (ja) | 2014-10-09 | 2023-06-13 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022048153A JP2022048153A (ja) | 2022-03-25 |
| JP2022048153A5 true JP2022048153A5 (enExample) | 2022-09-20 |
| JP7300763B2 JP7300763B2 (ja) | 2023-06-30 |
Family
ID=55652864
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552830A Active JP6161098B2 (ja) | 2014-10-09 | 2015-10-06 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2017111736A Active JP6683990B2 (ja) | 2014-10-09 | 2017-06-06 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2020048623A Active JP7008350B2 (ja) | 2014-10-09 | 2020-03-19 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2021213604A Active JP7300763B2 (ja) | 2014-10-09 | 2021-12-28 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2023097065A Active JP7527049B2 (ja) | 2014-10-09 | 2023-06-13 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2024113188A Active JP7755890B2 (ja) | 2014-10-09 | 2024-07-16 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552830A Active JP6161098B2 (ja) | 2014-10-09 | 2015-10-06 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2017111736A Active JP6683990B2 (ja) | 2014-10-09 | 2017-06-06 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2020048623A Active JP7008350B2 (ja) | 2014-10-09 | 2020-03-19 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023097065A Active JP7527049B2 (ja) | 2014-10-09 | 2023-06-13 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
| JP2024113188A Active JP7755890B2 (ja) | 2014-10-09 | 2024-07-16 | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US10316102B2 (enExample) |
| EP (2) | EP3597742B1 (enExample) |
| JP (6) | JP6161098B2 (enExample) |
| KR (1) | KR101890638B1 (enExample) |
| CN (1) | CN107109421B (enExample) |
| AU (1) | AU2015329444B2 (enExample) |
| BR (1) | BR112017006710B1 (enExample) |
| CA (1) | CA2962375C (enExample) |
| CY (1) | CY1122324T1 (enExample) |
| DK (2) | DK3205720T3 (enExample) |
| ES (2) | ES2927366T3 (enExample) |
| HR (2) | HRP20191839T1 (enExample) |
| HU (2) | HUE060047T2 (enExample) |
| IL (1) | IL251504B (enExample) |
| LT (2) | LT3205720T (enExample) |
| MX (1) | MX358472B (enExample) |
| MY (1) | MY167722A (enExample) |
| NZ (1) | NZ730382A (enExample) |
| PH (1) | PH12017500596B1 (enExample) |
| PL (2) | PL3597742T3 (enExample) |
| PT (2) | PT3205720T (enExample) |
| RS (2) | RS59441B1 (enExample) |
| RU (1) | RU2670147C1 (enExample) |
| SG (1) | SG11201702391RA (enExample) |
| SI (2) | SI3597742T1 (enExample) |
| SM (1) | SMT201900663T1 (enExample) |
| TW (1) | TWI688651B (enExample) |
| WO (1) | WO2016056228A1 (enExample) |
| ZA (1) | ZA201701968B (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3597742T3 (pl) * | 2014-10-09 | 2022-11-14 | Yamaguchi University | Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR |
| GB201509413D0 (en) * | 2015-06-01 | 2015-07-15 | Ucl Business Plc | Fusion protein |
| CN108697798A (zh) | 2016-02-16 | 2018-10-23 | 达纳-法伯癌症研究所有限公司 | 免疫疗法组合物及方法 |
| AU2017235116B2 (en) * | 2016-03-17 | 2019-11-07 | Yamaguchi University | Immunocompetent cell and expression vector expressing regulatory factors of immune function |
| CA3048312A1 (en) * | 2017-01-01 | 2018-07-05 | Chi-Yu Gregory Lee | Rp215 chimeric antigen receptor construct and methods of making and using same |
| BR112019013947A2 (pt) | 2017-01-10 | 2020-02-11 | Yamaguchi University | Anticorpo, receptor de antígeno quimérico, célula imunocompetente, gene de anticorpo, vetor, célula hospedeira, método para detectar gpc3, e, kit para a detecção de gpc3. |
| RU2770002C2 (ru) * | 2017-03-27 | 2022-04-14 | Нойл-Иммьюн Байотек, Инк. | Химерный антигенный рецептор |
| CN108484777B (zh) * | 2017-03-31 | 2022-07-12 | 李吉祐 | 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用 |
| ES2970282T3 (es) | 2017-10-10 | 2024-05-27 | Univ Yamaguchi | Potenciador de células T o células B que tienen función memoria, inhibidor de la recurrencia de tumores malignos e inductor para inducir la función memoria en células T o células B |
| EA202091488A1 (ru) * | 2017-12-24 | 2020-09-23 | Нойл-Иммьюн Байотек, Инк. | Иммунокомпетентная клетка, которая экспрессирует молекулу клеточной поверхности, специфически распознающую человеческий мезотелин, il-7 и ccl19 |
| TWI894123B (zh) * | 2017-12-27 | 2025-08-21 | 日商武田藥品工業有限公司 | 含核酸之脂質奈米粒子及其用途 |
| CN108659133A (zh) * | 2018-04-26 | 2018-10-16 | 上海怡豪生物科技有限公司 | 肺癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN108641000A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 肝癌的双靶点car-t治疗载体及其构建方法和应用 |
| CN108641001A (zh) * | 2018-04-26 | 2018-10-12 | 上海怡豪生物科技有限公司 | 结肠癌的双靶点car-t治疗载体及其构建方法和应用 |
| WO2019219029A1 (zh) * | 2018-05-15 | 2019-11-21 | 科济生物医药（上海）有限公司 | 基因工程化的细胞及应用 |
| KR20190141511A (ko) * | 2018-06-14 | 2019-12-24 | 주식회사 녹십자랩셀 | 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포 |
| CN108866004A (zh) * | 2018-06-26 | 2018-11-23 | 奥妙生物技术（广州）有限公司 | Shp-1敲除的t细胞及其构建方法 |
| JP2021530444A (ja) | 2018-06-28 | 2021-11-11 | ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド | 固形および液体悪性病変における多重ｃａｒ ｔ細胞での複数抗原の標的化 |
| US20230071098A1 (en) * | 2018-07-17 | 2023-03-09 | Noile-Immune Biotech, Inc. | Anti-gpc3 single-chain antibody-containing car |
| CN109055430A (zh) * | 2018-08-14 | 2018-12-21 | 杭州荣泽生物科技有限公司 | 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法 |
| WO2020045610A1 (ja) * | 2018-08-31 | 2020-03-05 | ノイルイミューン・バイオテック株式会社 | Ｃａｒ発現ｔ細胞及びｃａｒ発現ベクター |
| CA3111978A1 (en) * | 2018-09-05 | 2020-03-12 | Seogkyoung KONG | Chimeric antigen receptor for solid cancer and t cells expressing chimeric antigen receptor |
| CN112771167B (zh) * | 2018-09-20 | 2025-09-26 | 克莱格医学有限公司 | 表达有趋化因子的细胞及用途 |
| EP3864142A4 (en) * | 2018-10-12 | 2023-07-19 | iCell Gene Therapeutics LLC | CHEMERA ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
| CN109504660B (zh) * | 2018-11-02 | 2021-08-06 | 温州启星生物技术有限公司 | 一种第四代car-t细胞及其构建方法和应用 |
| WO2020106621A1 (en) * | 2018-11-19 | 2020-05-28 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| CN113543792A (zh) * | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| CN113646426B (zh) * | 2019-04-04 | 2024-09-13 | 上海医药集团股份有限公司 | 一种包含肿瘤抗原识别受体的免疫细胞及其应用 |
| CN112080526A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 表达il-7和car的表达载体及免疫细胞 |
| CN112080525A (zh) * | 2019-06-14 | 2020-12-15 | 南京艾德免疫治疗研究院有限公司 | 一种改良型嵌合抗原受体t细胞的制备 |
| JP7769325B2 (ja) * | 2019-07-23 | 2025-11-13 | 株式会社東芝 | Ｃａｒ－ｔ細胞の製造方法、核酸導入キャリア及びキット |
| MY209383A (en) | 2019-10-28 | 2025-07-05 | Noile Immune Biotech Inc | Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product |
| CN110922490B (zh) * | 2019-12-05 | 2023-03-03 | 浙江启新生物技术有限公司 | 分泌白介素7和趋化因子21的car表达载体及应用 |
| CN115427451A (zh) * | 2020-02-14 | 2022-12-02 | 北京永泰瑞科生物科技有限公司 | 过表达从外部导入的细胞信号调节因子的免疫细胞及其用途 |
| JP2021142159A (ja) * | 2020-03-12 | 2021-09-24 | 株式会社三洋物産 | 遊技機 |
| JP2021142156A (ja) * | 2020-03-12 | 2021-09-24 | 株式会社三洋物産 | 遊技機 |
| JP2021142158A (ja) * | 2020-03-12 | 2021-09-24 | 株式会社三洋物産 | 遊技機 |
| WO2021213479A1 (zh) * | 2020-04-22 | 2021-10-28 | 复星凯特生物科技有限公司 | Shp2特异性失活突变蛋白及其在car-t治疗中应用 |
| GB202006820D0 (en) * | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
| JPWO2021256522A1 (enExample) | 2020-06-17 | 2021-12-23 | ||
| KR102297396B1 (ko) | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| EP4261225A4 (en) | 2020-12-10 | 2024-11-13 | Eutilex Co., Ltd. | ANTI-PD-1 ANTIBODY AND ITS USES |
| CN114717203B (zh) * | 2020-12-22 | 2023-06-27 | 广东东阳光药业有限公司 | 一种hIL7/hCCL19双基因重组溶瘤病毒及其制备方法和用途 |
| CN114716548B (zh) | 2021-01-05 | 2024-11-05 | (株)爱恩德生物 | 抗-fgfr3抗体及其用途 |
| CN112961248B (zh) * | 2021-02-22 | 2022-03-18 | 广州百暨基因科技有限公司 | 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用 |
| KR102568745B1 (ko) | 2021-05-18 | 2023-08-24 | 주식회사 바이오솔루션 | 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법 |
| TW202321287A (zh) | 2021-07-29 | 2023-06-01 | 日商武田藥品工業股份有限公司 | 特異性靶向間皮素之經工程改造之免疫細胞及其用途 |
| CN113913385A (zh) * | 2021-09-01 | 2022-01-11 | 苏州璞惠卓越生物科技有限公司 | 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途 |
| CN113921082B (zh) * | 2021-10-27 | 2023-04-07 | 云舟生物科技(广州)股份有限公司 | 基因搜索权重调整方法、计算机存储介质及电子设备 |
| US20250230215A1 (en) * | 2021-11-08 | 2025-07-17 | Memorial Sloan-Kettering Cancer Center | Immune cells expressing glucose transporter 5 (glut5) and compositions and methods including the same |
| WO2023223292A1 (en) * | 2022-05-20 | 2023-11-23 | Takeda Pharmaceutical Company Limited | Methods of producing engineered immune cells |
| US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
| AU2023313641A1 (en) | 2022-07-26 | 2025-03-13 | Aimed Bio Inc. | Anti-ror1 antibody and use thereof |
| CN115505601B (zh) * | 2022-10-17 | 2024-05-28 | 深圳市先康达生命科学有限公司 | 一种两级SynNotch逻辑调控结构及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857318A (ja) * | 1981-10-01 | 1983-04-05 | Nippon Koutai Kenkyusho:Kk | 癌細胞障害性リンパ球の製造法 |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| KR20050118057A (ko) * | 2004-04-24 | 2005-12-15 | 김상희 | 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품 |
| TWI436775B (zh) * | 2007-08-24 | 2014-05-11 | Oncotherapy Science Inc | 以抗原胜肽合併化療藥劑治療胰臟癌 |
| JP2012504959A (ja) | 2008-10-08 | 2012-03-01 | イントレキソン コーポレーション | 複数の免疫モジュレーターを発現する遺伝子操作された細胞およびその使用 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| EP2651442B1 (en) * | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| CN107188969B (zh) | 2011-04-08 | 2021-08-27 | 美国卫生和人力服务部 | 抗-表皮生长因子受体变体iii嵌合抗原受体及其用于治疗癌症的用途 |
| US20130071414A1 (en) * | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| US20140255363A1 (en) * | 2011-09-16 | 2014-09-11 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| EP2765193B1 (en) | 2011-10-07 | 2017-08-09 | Mie University | Chimeric antigen receptor |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| MX2014010185A (es) * | 2012-02-22 | 2014-11-14 | Univ Pennsylvania | Uso de dominio de señalizacion cd2 en receptores de antigeno quimericos de segunda generacion. |
| CN102625373A (zh) * | 2012-02-22 | 2012-08-01 | 中兴通讯股份有限公司 | 一种智能载波管理方法及装置 |
| PL3597742T3 (pl) * | 2014-10-09 | 2022-11-14 | Yamaguchi University | Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR |
-
2015
- 2015-10-06 PL PL19196196.0T patent/PL3597742T3/pl unknown
- 2015-10-06 DK DK15849416.1T patent/DK3205720T3/da active
- 2015-10-06 EP EP19196196.0A patent/EP3597742B1/en active Active
- 2015-10-06 PL PL15849416T patent/PL3205720T3/pl unknown
- 2015-10-06 JP JP2016552830A patent/JP6161098B2/ja active Active
- 2015-10-06 KR KR1020177009895A patent/KR101890638B1/ko active Active
- 2015-10-06 HU HUE19196196A patent/HUE060047T2/hu unknown
- 2015-10-06 LT LT15849416T patent/LT3205720T/lt unknown
- 2015-10-06 WO PCT/JP2015/005080 patent/WO2016056228A1/ja not_active Ceased
- 2015-10-06 RS RSP20191315 patent/RS59441B1/sr unknown
- 2015-10-06 AU AU2015329444A patent/AU2015329444B2/en active Active
- 2015-10-06 PT PT158494161T patent/PT3205720T/pt unknown
- 2015-10-06 CN CN201580053922.1A patent/CN107109421B/zh active Active
- 2015-10-06 SI SI201531887T patent/SI3597742T1/sl unknown
- 2015-10-06 HR HRP20191839TT patent/HRP20191839T1/hr unknown
- 2015-10-06 HU HUE15849416A patent/HUE046710T2/hu unknown
- 2015-10-06 EP EP15849416.1A patent/EP3205720B1/en active Active
- 2015-10-06 SM SM20190663T patent/SMT201900663T1/it unknown
- 2015-10-06 MX MX2017004393A patent/MX358472B/es active IP Right Grant
- 2015-10-06 LT LTEP19196196.0T patent/LT3597742T/lt unknown
- 2015-10-06 MY MYPI2017701137A patent/MY167722A/en unknown
- 2015-10-06 RU RU2017114545A patent/RU2670147C1/ru active
- 2015-10-06 PT PT191961960T patent/PT3597742T/pt unknown
- 2015-10-06 SI SI201530950T patent/SI3205720T1/sl unknown
- 2015-10-06 RS RS20220895A patent/RS63601B1/sr unknown
- 2015-10-06 CA CA2962375A patent/CA2962375C/en active Active
- 2015-10-06 DK DK19196196.0T patent/DK3597742T3/da active
- 2015-10-06 BR BR112017006710A patent/BR112017006710B1/pt active IP Right Grant
- 2015-10-06 ES ES19196196T patent/ES2927366T3/es active Active
- 2015-10-06 SG SG11201702391RA patent/SG11201702391RA/en unknown
- 2015-10-06 NZ NZ730382A patent/NZ730382A/en unknown
- 2015-10-06 HR HRP20221211TT patent/HRP20221211T1/hr unknown
- 2015-10-06 ES ES15849416T patent/ES2751945T3/es active Active
- 2015-10-06 US US15/513,870 patent/US10316102B2/en active Active
- 2015-10-08 TW TW104133272A patent/TWI688651B/zh active
-
2017
- 2017-03-22 ZA ZA2017/01968A patent/ZA201701968B/en unknown
- 2017-03-31 PH PH12017500596A patent/PH12017500596B1/en unknown
- 2017-04-02 IL IL251504A patent/IL251504B/en active IP Right Grant
- 2017-06-06 JP JP2017111736A patent/JP6683990B2/ja active Active
-
2019
- 2019-05-06 US US16/404,165 patent/US10906984B2/en active Active
- 2019-11-26 CY CY20191101239T patent/CY1122324T1/el unknown
-
2020
- 2020-03-19 JP JP2020048623A patent/JP7008350B2/ja active Active
- 2020-12-23 US US17/133,286 patent/US20210253726A1/en not_active Abandoned
-
2021
- 2021-12-28 JP JP2021213604A patent/JP7300763B2/ja active Active
-
2023
- 2023-06-13 JP JP2023097065A patent/JP7527049B2/ja active Active
-
2024
- 2024-07-16 JP JP2024113188A patent/JP7755890B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022048153A5 (enExample) | ||
| Qu et al. | Tumor buster-where will the CAR-T cell therapy ‘missile’go? | |
| Stork et al. | Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives | |
| Li et al. | Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice | |
| JP2019522054A5 (enExample) | ||
| Song et al. | In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB) | |
| JP2020506962A5 (enExample) | ||
| HRP20221211T1 (hr) | Car-izražavajući vektor i t-stanice koje izražavaju car | |
| JP2020108398A5 (enExample) | ||
| JP2021502104A5 (enExample) | ||
| JP2020517259A5 (enExample) | ||
| Janes et al. | Antibody targeting of Eph receptors in cancer | |
| JP2021503892A5 (enExample) | ||
| JP2017513470A5 (enExample) | ||
| JP2019513777A5 (enExample) | ||
| FI3611192T3 (fi) | Tcr alfa/beeta-reaktiivisuuteen perustuvia, t-soluja rekrytoivia polypeptidejä | |
| Shiozawa et al. | Pharmacologically upregulated carcinoembryonic antigen-expression enhances the cytolytic activity of genetically-modified chimeric antigen receptor NK-92MI against colorectal cancer cells | |
| JP2015535689A5 (enExample) | ||
| JP2018512168A5 (enExample) | ||
| JP2009526823A5 (enExample) | ||
| FI3294319T3 (fi) | Cd3-reaktiivisuuteen perustuen t-soluja rekrytoivia polypeptidejä | |
| JPWO2019213610A5 (enExample) | ||
| JP2013227339A5 (enExample) | ||
| JP2015517470A5 (enExample) | ||
| Canella et al. | Therapeutic utility of engineered myeloid cells in the tumor microenvironment |